Is POLB or CIR more profitable?

Circassia Group's return on equity of 0.00% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -71.28% -21.33% Circassia Group N/A N/A N/A

Is POLB or TILS more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -71.28% -21.33% Tiziana Life Sciences N/A N/A N/A

Which has better valuation & earnings, VSN or POLB?

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verseon N/A N/A N/A -£14.30 N/A Poolbeg Pharma N/A N/A -£4.50B -£0.79 N/A

Is VSN or POLB more profitable?

Verseon's return on equity of 0.00% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Verseon N/A N/A N/A Poolbeg Pharma N/A -71.28% -21.33%

Is POLB or SCLP more profitable?

Poolbeg Pharma has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 128.87% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -71.28% -21.33% Scancell -116.98% 128.87% -45.28%

Does the media prefer POLB or SCLP?

In the previous week, Scancell had 2 more articles in the media than Poolbeg Pharma. MarketBeat recorded 7 mentions for Scancell and 5 mentions for Poolbeg Pharma. Poolbeg Pharma's average media sentiment score of 0.53 beat Scancell's score of -0.04 indicating that Poolbeg Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Poolbeg Pharma 0 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scancell 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Poolbeg Pharma (POLB) Competitors

GBX 6.80 -0.10 (-1.45%)

As of 05:49 AM Eastern

Compare

POLB vs. ARIX, CIR, TILS, VSN, and SCLP

Should you buy Poolbeg Pharma stock or one of its competitors? Poolbeg Pharma's main competitors and comparable companies include Arix Bioscience (ARIX), Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), and Scancell (SCLP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Poolbeg Pharma compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and Poolbeg Pharma (LON:POLB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Arix Bioscience has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.79	N/A

In the previous week, Poolbeg Pharma had 5 more articles in the media than Arix Bioscience. MarketBeat recorded 5 mentions for Poolbeg Pharma and 0 mentions for Arix Bioscience. Poolbeg Pharma's average media sentiment score of 0.53 beat Arix Bioscience's score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Arix Bioscience	Neutral
Poolbeg Pharma	Positive

Arix Bioscience has a net margin of 105.64% compared to Poolbeg Pharma's net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
Poolbeg Pharma	N/A	-71.28%	-21.33%

41.3% of Arix Bioscience shares are owned by institutional investors. Comparatively, 1.5% of Poolbeg Pharma shares are owned by institutional investors. 20.7% of Arix Bioscience shares are owned by company insiders. Comparatively, 7.5% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Arix Bioscience has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.828, meaning that its stock price is 83% more volatile than the broader market.

Summary

Arix Bioscience beats Poolbeg Pharma on 9 of the 12 factors compared between the two stocks.

How does Poolbeg Pharma compare to Circassia Group?

Poolbeg Pharma (LON:POLB) and Circassia Group (LON:CIR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, Poolbeg Pharma had 5 more articles in the media than Circassia Group. MarketBeat recorded 5 mentions for Poolbeg Pharma and 0 mentions for Circassia Group. Poolbeg Pharma's average media sentiment score of 0.53 beat Circassia Group's score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Poolbeg Pharma	Positive
Circassia Group	Neutral

1.5% of Poolbeg Pharma shares are owned by institutional investors. 7.5% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Circassia Group has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.79	N/A
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A

Circassia Group's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-71.28%	-21.33%
Circassia Group	N/A	N/A	N/A

Summary

Circassia Group beats Poolbeg Pharma on 5 of the 9 factors compared between the two stocks.

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Poolbeg Pharma (LON:POLB) and Tiziana Life Sciences (LON:TILS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Tiziana Life Sciences has lower revenue, but higher earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.79	N/A
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A

1.5% of Poolbeg Pharma shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tiziana Life Sciences' return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-71.28%	-21.33%
Tiziana Life Sciences	N/A	N/A	N/A

In the previous week, Poolbeg Pharma had 5 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 5 mentions for Poolbeg Pharma and 0 mentions for Tiziana Life Sciences. Poolbeg Pharma's average media sentiment score of 0.53 beat Tiziana Life Sciences' score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Poolbeg Pharma	Positive
Tiziana Life Sciences	Neutral

Summary

Poolbeg Pharma beats Tiziana Life Sciences on 6 of the 9 factors compared between the two stocks.

How does Poolbeg Pharma compare to Verseon?

Verseon (LON:VSN) and Poolbeg Pharma (LON:POLB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

1.5% of Poolbeg Pharma shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Poolbeg Pharma had 5 more articles in the media than Verseon. MarketBeat recorded 5 mentions for Poolbeg Pharma and 0 mentions for Verseon. Poolbeg Pharma's average media sentiment score of 0.53 beat Verseon's score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Verseon	Neutral
Poolbeg Pharma	Positive

Verseon's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verseon	N/A	N/A	N/A
Poolbeg Pharma	N/A	-71.28%	-21.33%

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verseon	N/A	N/A	N/A	-£14.30	N/A
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.79	N/A

Summary

Poolbeg Pharma beats Verseon on 5 of the 8 factors compared between the two stocks.

How does Poolbeg Pharma compare to Scancell?

Poolbeg Pharma (LON:POLB) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

1.5% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 1.3% of Scancell shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by insiders. Comparatively, 13.2% of Scancell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Poolbeg Pharma has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 128.87% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-71.28%	-21.33%
Scancell	-116.98%	128.87%	-45.28%

Scancell has higher revenue and earnings than Poolbeg Pharma. Scancell is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.79	N/A
Scancell	£4.71M	26.78	-£6.75M	-£0.55	N/A

Poolbeg Pharma has a beta of 1.828, suggesting that its stock price is 83% more volatile than the broader market. Comparatively, Scancell has a beta of 0.685, suggesting that its stock price is 32% less volatile than the broader market.

In the previous week, Scancell had 2 more articles in the media than Poolbeg Pharma. MarketBeat recorded 7 mentions for Scancell and 5 mentions for Poolbeg Pharma. Poolbeg Pharma's average media sentiment score of 0.53 beat Scancell's score of -0.04 indicating that Poolbeg Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Poolbeg Pharma	0 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scancell	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Poolbeg Pharma and Scancell tied by winning 6 of the 12 factors compared between the two stocks.

Get Poolbeg Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

POLB vs. The Competition

Export

Metric	Poolbeg Pharma	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£51.91M	£3.93B	£7.25B	£2.81B
Dividend Yield	N/A	3.65%	2.53%	6.27%
P/E Ratio	-8.61	13.62	275.59	367.14
Price / Sales	N/A	1,133.57	559.90	88,518.93
Price / Cash	2.11	39.46	27.30	27.87
Price / Book	0.00	17.76	11.02	7.31
Net Income	-£4.50B	-£22.69M	£3.50B	£5.89B
7 Day Performance	-2.86%	-1.56%	-1.24%	0.13%
1 Month Performance	-19.02%	-7.88%	-4.01%	-0.41%
1 Year Performance	83.78%	14.38%	7.20%	22.78%

Poolbeg Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
POLB Poolbeg Pharma	N/A	GBX 6.80 -1.4%	N/A	+86.5%	£51.91M	N/A	N/A	12
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9
CIR Circassia Group	N/A	N/A	N/A	N/A	£142.66M	£27.90M	3,400.00	111	Gap Down
TILS Tiziana Life Sciences	N/A	N/A	N/A	N/A	£113.85M	-£3.60M	N/A	11
VSN Verseon	N/A	N/A	N/A	N/A	£112.24M	N/A	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:POLB) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Poolbeg Pharma (POLB) Competitors

POLB vs. ARIX, CIR, TILS, VSN, and SCLP

How does Poolbeg Pharma compare to Arix Bioscience?

Summary

How does Poolbeg Pharma compare to Circassia Group?

Summary

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Summary

How does Poolbeg Pharma compare to Verseon?

Summary

How does Poolbeg Pharma compare to Scancell?

Summary

Media Sentiment Over Time

POLB vs. The Competition

Poolbeg Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Poolbeg Pharma (POLB) Competitors

POLB vs. ARIX, CIR, TILS, VSN, and SCLP

How does Poolbeg Pharma compare to Arix Bioscience?

Which has higher valuation and earnings, ARIX or POLB?

Does the media refer more to ARIX or POLB?

Is ARIX or POLB more profitable?

Do insiders and institutionals hold more shares of ARIX or POLB?

Which has more risk & volatility, ARIX or POLB?

Summary

How does Poolbeg Pharma compare to Circassia Group?

Does the media favor POLB or CIR?

Do insiders & institutionals believe in POLB or CIR?

Which has better earnings and valuation, POLB or CIR?

Is POLB or CIR more profitable?

Summary

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Which has preferable earnings & valuation, POLB or TILS?

Do institutionals and insiders hold more shares of POLB or TILS?

Is POLB or TILS more profitable?

Does the media prefer POLB or TILS?

Summary

How does Poolbeg Pharma compare to Verseon?

Do insiders & institutionals believe in VSN or POLB?

Does the media refer more to VSN or POLB?

Is VSN or POLB more profitable?

Which has better valuation & earnings, VSN or POLB?

Summary

How does Poolbeg Pharma compare to Scancell?

Do institutionals and insiders believe in POLB or SCLP?

Is POLB or SCLP more profitable?

Which has higher earnings and valuation, POLB or SCLP?

Which has more risk & volatility, POLB or SCLP?

Does the media prefer POLB or SCLP?

Summary

Media Sentiment Over Time

POLB vs. The Competition

Poolbeg Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools